166 related articles for article (PubMed ID: 35540908)
1. LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways.
Kadi AA; Attwa MW; Darwish HW
RSC Adv; 2018 Jan; 8(3):1182-1190. PubMed ID: 35540908
[TBL] [Abstract][Full Text] [Related]
2. Identification of reactive intermediate formation and bioactivation pathways in Abemaciclib metabolism by LC-MS/MS:
Kadi AA; Darwish HW; Abuelizz HA; Alsubi TA; Attwa MW
R Soc Open Sci; 2019 Jan; 6(1):181714. PubMed ID: 30800400
[TBL] [Abstract][Full Text] [Related]
3. Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS:
Attwa MW; Kadi AA; Abdelhameed AS
RSC Adv; 2018 Nov; 8(68):38733-38744. PubMed ID: 35558335
[TBL] [Abstract][Full Text] [Related]
4. Investigation of Fenebrutinib Metabolism and Bioactivation Using MS
Alsibaee AM; Aljohar HI; Attwa MW; Abdelhameed AS; Kadi AA
Molecules; 2023 May; 28(10):. PubMed ID: 37241965
[TBL] [Abstract][Full Text] [Related]
5. Reactive intermediates in copanlisib metabolism identified by LC-MS/MS: phase I metabolic profiling.
AlRabiah H; Kadi AA; Attwa MW; Abdelhameed AS; Mostafa GAE
RSC Adv; 2019 Feb; 9(11):6409-6418. PubMed ID: 35517257
[TBL] [Abstract][Full Text] [Related]
6. LC-MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation.
Attwa MW; Kadi AA; Alrabiah H; Darwish HW
J Pharm Biomed Anal; 2018 Oct; 160():19-30. PubMed ID: 30055343
[TBL] [Abstract][Full Text] [Related]
7. Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation.
Abdelhameed AS; Attwa MW; Kadi AA
Molecules; 2020 Oct; 25(21):. PubMed ID: 33126762
[TBL] [Abstract][Full Text] [Related]
8. Belizatinib: Novel reactive intermediates and bioactivation pathways characterized by LC-MS/MS.
Attwa MW; Kadi AA; Darwish HW
J Pharm Biomed Anal; 2019 Jul; 171():132-147. PubMed ID: 30999224
[TBL] [Abstract][Full Text] [Related]
9. Phase I metabolic profiling and unexpected reactive metabolites in human liver microsome incubations of X-376 using LC-MS/MS: bioactivation pathway elucidation and
Attwa MW; Kadi AA; Abdelhameed AS
RSC Adv; 2020 Jan; 10(9):5412-5427. PubMed ID: 35498318
[TBL] [Abstract][Full Text] [Related]
10. LC-MS/MS reveals the formation of reactive ortho-quinone and iminium intermediates in saracatinib metabolism: Phase I metabolic profiling.
Attwa MW; Kadi AA; Darwish HW; Alrabiah H
Clin Chim Acta; 2018 Jul; 482():84-94. PubMed ID: 29614307
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Stable and Reactive Metabolites of the Anticancer Drug, Ensartinib, in Human Liver Microsomes Using LC-MS/MS: An in silico and Practical Bioactivation Approach.
Abdelhameed AS; Attwa MW; Kadi AA
Drug Des Devel Ther; 2020; 14():5259-5273. PubMed ID: 33299299
[TBL] [Abstract][Full Text] [Related]
12. Detection and characterization of olmutinib reactive metabolites by LC-MS/MS: Elucidation of bioactivation pathways.
Attwa MW; Kadi AA; Abdelhameed AS
J Sep Sci; 2020 Feb; 43(4):708-718. PubMed ID: 31788977
[TBL] [Abstract][Full Text] [Related]
13. Reactive intermediates formation and bioactivation pathways of spebrutinib revealed by LC-MS/MS:
Alsibaee AM; Aljohar HI; Attwa MW; Abdelhameed AS; Kadi AA
Heliyon; 2023 Jun; 9(6):e17058. PubMed ID: 37484253
[TBL] [Abstract][Full Text] [Related]
14. Ion Trap LC/MS reveals the generation of reactive intermediates in acalabrutinib metabolism: phase I metabolic profiling and bioactivation pathways elucidation.
Alsibaee AM; Aljohar HI; Attwa MW; Abdelhameed AS; Kadi AA
RSC Adv; 2024 May; 14(23):16170-16193. PubMed ID: 38769961
[TBL] [Abstract][Full Text] [Related]
15. Sapitinib: reactive intermediates and bioactivation pathways characterized by LC-MS/MS.
Attwa MW; Kadi AA
RSC Adv; 2019 Oct; 9(57):32995-33006. PubMed ID: 35529145
[TBL] [Abstract][Full Text] [Related]
16. Investigation of metabolic stability of the novel ALK inhibitor brigatinib by liquid chromatography tandem mass spectrometry.
Darwish HW; Kadi AA; Attwa MW; Almutairi HS
Clin Chim Acta; 2018 May; 480():180-185. PubMed ID: 29458050
[TBL] [Abstract][Full Text] [Related]
17.
Alsubi TA; Attwa MW; Bakheit AH; Darwish HW; Abuelizz HA; Kadi AA
RSC Adv; 2020 Jun; 10(38):22668-22683. PubMed ID: 35514564
[TBL] [Abstract][Full Text] [Related]
18. Reactive intermediates and bioactivation pathways characterization of avitinib by LC-MS/MS: In vitro metabolic investigation.
Attwa MW; Kadi AA; Abdelhameed AS
J Pharm Biomed Anal; 2019 Feb; 164():659-667. PubMed ID: 30472584
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of
Al-Shakliah NS; Attwa MW; Kadi AA; AlRabiah H
RSC Adv; 2020 Apr; 10(28):16231-16244. PubMed ID: 35498820
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of in vivo, in vitro and reactive metabolites of vandetanib using LC-ESI-MS/MS.
Attwa MW; Kadi AA; Darwish HW; Amer SM; Al-Shakliah NS
Chem Cent J; 2018 Sep; 12(1):99. PubMed ID: 30251155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
